Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe.

The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region.

For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi Sankyo, he held senior leadership roles across Medical Affairs and Commercial in the EU region, Asia, and global functions. Markus began his career as a physician at Münster University Hospital, where he practiced for nine years, and continues to teach as a Professor of Internal Medicine at the University of Münster. He also serves as a member of the Board of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

“Europe will continue to play a pivotal role in our company’s success. Markus has consistently demonstrated the ability to combine strategic vision with operational execution while building high-performing teams. He is the right leader to guide our European organization into its next phase of growth,” said Ken Keller, who has been appointed to the newly created role of Chief Commercialization Officer, also effective April 1, 2027.

“As our portfolio continues to grow, so does the complexity of how we bring innovation to patients. Our responsibility is to make that complexity easier to navigate – by creating clarity, aligning around shared priorities and focusing our expertise where it creates the greatest impact. By working as one integrated organization, we can bring innovative medicines to more patients across Europe, faster and more effectively,” said Markus Kosch.

The new European commercial organization forms part of the broader strategy of Daiichi Sankyo for the next five years, designed to streamline commercialization, strengthen collaboration across regions and functions and support the anticipated launch of multiple new indications by 2030.

Together, these changes demonstrate the company's commitment to creating a more connected, future-ready business capable of translating science and technology into greater value for patients, healthcare systems and society.

About Daiichi Sankyo

Daiichi Sankyo (TSE: 4568) is a global healthcare company committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of contributing to the enrichment of quality of life around the world. With a strategic focus on oncology, Daiichi Sankyo is advancing an industry-leading antibody drug conjugate portfolio along with identifying new breakthrough generating technologies to deliver practice-changing medicines to patients, healthcare professionals and society. For more information, please visit www.daiichisankyo.eu.